|
Hologic is submitting this report in accordance with 21.Cfr part 803.The submission is based upon the currently available information.The submission of this report does not represent confirmation of device malfunction involving the hologic products in the event described.Lot/serial number of the device not provided by the complainant; therefore, the udi, expiration and manufacturing dates are not known.Device history record (dhr) review was unable to be conducted for the disposable device as the identification numbers were not provided by the complainant.The device involved in this event was not returned for evaluation purposes therefore visual and functional analysis of the product could not be performed.We are unable to confirm a relationship between the device and the issue reported.The information obtained during complaint investigation will be included in our global complaint trending and product surveillance will continue to monitor complaints of this type for adverse trends.If the product is received or additional information is obtained, the investigation will be reopened accordingly per standard operating procedure.
|
|
It was reported that a patient received a biozorb device implant on (b)(6) 2022, "the biozorb implant was problematic from beginning.Breast incision would not heal - which delayed radiation.Then - painful all the time.Emotionally felt like cancer lump was never removed.Requested its removal only to be reassured it would dissolve -advised to be patient.Finally, the doctor agreed for it to be removed surgically." additional information was received from the patient in which it was reported that the surgical incision site would not heal after trying three antibiotics, resulting in the patient's radiation treatments being delayed by almost a month.The patient further reports a lump in the exact location of her previous cancer that was painful to touch.It is reported that the biozorb device was surgically removed on (b)(6) 2025.No further information is currently available.
|
|
An investigation was conducted: brief description: it was reported that a patient received a biozorb device implant on (b)(6), 2022, "the biozorb implant was problematic from beginning.Breast incision would not heal - which delayed radiation.Then - painful all the time.Emotionally felt like cancer lump was never removed.Requested its removal only to be reassured it would dissolve -advised to be patient.Finally, the doctor agreed for it to be removed surgically." additional information was received from the patient in which it was reported that the surgical incision site would not heal after trying three antibiotics, resulting in the patient's radiation treatments being delayed by almost a month.The patient further reports a lump in the exact location of her previous cancer that was painful to touch.It is reported that the biozorb device was surgically removed on (b)(6), 2025.No further information is currently available.Investigation methods and findings: the sample was not returned to the post market quality laboratory for further investigation; therefore, the inspection according to the biozorb post market instructions was not able to be conducted for this complaint.Additionally, there was limited patient-related information provided for this event; consequently, a comprehensive investigation could not be conducted.The harms identified, based on clinical symptoms and hazardous situations for this complaint are: - pain, serious (pain, sleep dysfunction, device palpability, failure to resorb).- infection, serious (infection).- scar tissue, minor (scar tissue / delayed wound healing).- additional intervention/treatment/scan required, critical (additional surgery/device explanation, calcifications).Cause/root cause: the described issue was investigated through a root cause analysis conducted under capa.The initial purpose of this capa was to evaluate the biozorb product for a root cause linking the product design to the reported complaint issues.The results of the root cause assessment did not find any direct link between the device and the reported complaint issues.Consequently, the implementation activities from capa were considered no longer applicable since hologic has ceased selling the biozorb product with no intention of returning it to market.In addition, capa is currently evaluating the biozorb product¿s entire dhf and is actively under remediation.Furthermore, a voluntary recall for the biozorb product was initiated on october 24, 2024.Conclusion: the reported issue could not be confirmed as no sample was returned for evaluation.The risk trending analysis does not increase the risk zone index.The potential root cause analysis was assessed under capa.Capa is currently evaluating the biozorb product¿s entire dhf and is actively under remediation.The risks associated with this event are further detailed and evaluated against the product and its hazard analysis within the health risk assessment biozorb, complaint evaluation.Future events will be monitored and trended.Complaint confirmed: no.Device history record (dhr) review: not performed.No lot number was provided; therefore, no dhr could be located or reviewed.
|